Australian radiopharma company Telix Pharmaceuticals Ltd. announced it is acquiring its partner, Belgium-based Advanced Nuclear Medicine Ingredients (Anmi) SA, for roughly A$8.1 million (US$5.9 million) in cash and Telix shares. The move accelerates commercialization of Telix's prostate cancer diagnostic kit, Illumet, in the U.S. and Europe.